Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Contact Us

Send us a Message


MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Scientists compared 51 longevity studies to see which aging biomarkers respond most reliably

25

Aug 2026

Scientists compared 51 longevity studies to see which aging biomarkers respond most reliably

Researchers analyzing 51 longitudinal intervention studies found that reliable generation 2+ DNA methylation biomarkers, particularly those predicting mortality or pace of aging, were the most responsive to interventions aimed at longevity or healthspan. Pharmacological and lifestyle interventions produced the strongest biomarker changes, but the authors cautioned that responsiveness does not yet establish these measures as validated surrogate endpoints for slower aging or longer life.

READ MORE
Higher BPA exposure tracked with higher estrogen and progesterone in women

24

Aug 2026

Higher BPA exposure tracked with higher estrogen and progesterone in women

Researchers found that higher urinary concentrations of BPA and several phthalate metabolites were associated with higher serum estrogen and progesterone levels in 90 premenopausal women from Iran. The cross-sectional study also identified positive associations for combined chemical exposures, although the authors cautioned that the mixture findings are exploratory and cannot establish causality.

READ MORE

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.